DNA methylation is essential for mammalian development and physiology. Here we report that the developmentally regulated H19 lncRNA binds to and inhibits S-adenosylhomocysteine hydrolase (SAHH), the only mammalian enzyme capable of hydrolysing S-adenosylhomocysteine (SAH). SAH is a potent feedback inhibitor of S-adenosylmethionine (SAM)-dependent methyltransferases that methylate diverse cellular components, including DNA, RNA, proteins, lipids and neurotransmitters. We show that H19 knockdown activates SAHH, leading to increased DNMT3B-mediated methylation of an lncRNA-encoding gene Nctc1 within the Igf2-H19-Nctc1 locus. Genome-wide methylation profiling reveals methylation changes at numerous gene loci consistent with SAHH modulation by H19. Our results uncover an unanticipated regulatory circuit involving broad epigenetic alterations by a single abundantly expressed lncRNA that may underlie gene methylation dynamics of development and diseases and suggest that this mode of regulation may extend to other cellular components.
Gene methylation (5-methyl-cytosine), accomplished by the joint action of three S-adenosylmethionine (SAM)-dependent DNA methyltransferases (DNMT1, DNMT3A and DNMT3B), plays a critical role in mammalian development and physiology. Altered gene methylation can cause developmental abnormalities and diseases. Being a dynamic process, methylation at a given gene locus is determined not only by the activity of the DNMTs, which have little sequence specificity, but also by local chromatin structure and modifications (that is, histone methylation and acetylation) that affect their accessibility1,2,3. DNMTs can also be targeted to specific gene loci via direct association with transcription factors4. Recent discoveries have marked long noncoding RNAs (lncRNAs) as new important players in DNA methylation regulation. lncRNAs can act in cis (at their site of transcription) or in trans (diffusing to other loci) to recruit chromatin-modifying complexes such as the Polycomb repressive complex 2 (PRC2) to affect chromatin structure and modifications5,6. In addition, the noncoding ecCEBPA transcript encoded within the CEBPA gene locus binds to DNMT1 and prevents CEBPA gene methylation7. This methylation blockade by DNMT1-interacting RNAs may extend to other genomic loci, although each of these RNAs acts locally, not genome wide7.
SAM-dependent methylation is central to the regulation of numerous biological processes. A wide spectrum of cellular components, including DNA, RNA, lipids, proteins and neurotransmitters, is subjected to methylation by SAM-dependent methyltransferases. SAM serves as the methyl-group donor during transmethylation reactions, yielding S-adenosylhomocysteine (SAH) as a by-product, which is a strong feedback inhibitor of most SAM-dependent transmethylation reactions. In mammals, S-adenosylhomocysteine hydrolase (SAHH) is the only known enzyme that catalyses the hydrolysis of SAH to homocysteine and adenosine, thereby relieving the inhibition8. A complete loss of SAHH is embryonic lethal9, whereas SAHH dysfunction results in numerous pathological consequences such as developmental abnormalities, neurovascular disorders, myopathy, cancer and childhood death10,11. Furthermore, inhibition of SAHH elicits antiviral effects12. Despite the pivotal roles that SAHH plays in a broad range of biological processes, how its activity is regulated remains poorly understood. Being an extraordinarily conserved enzyme (the human and mouse SAHH proteins share 97% identity), SAHH functions as a tetramer with cofactor NAD+/NADH bound to each subunit. Interaction with adenosine or copper inhibits SAHH activity8. Recently, lysine acetylation of SAHH has been reported to alter the structure and activity of this enzyme13. However, the biological significance of regulation of SAHH by these molecules and by acetylation is unclear. In addition, the possibility of SAHH regulation by other mechanisms remains to be explored.
The developmentally regulated imprinted H19, together with its co-regulated gene Igf2, plays important roles in embryo development and growth control and has been associated with human genetic disorders14. H19 is highly expressed in human and mouse placentas and fetal tissues as well as in a subset of postnatal and adult tissues including skeletal muscle15,16, heart17,18,19, haematopoietic stem cells20 and endometrium21. In addition, aberrant H19 expression has been detected in diverse human malignancies22. H19 encodes a polyadenylated lncRNA of ∼2.6 kb, which is predominantly cytoplasmic with a minor fraction also found in the nucleus14,23. H19 is a multifunctional lncRNA that has activities both in the nucleus and in the cytoplasm. Using genetically modified mouse models and cell culture systems, H19 has been shown to interact with the methyl-CpG-binding domain protein 1, that recruits repressive histone marks to imprinted network genes to inhibit transcription, thereby contributing to embryo growth regulation23. H19 also serves as a microRNA precursor for miR-675 that acts to inhibit placental growth24, maintain adult haematopoietic stem cells20, stimulate skeletal muscle differentiation and regeneration15 and promote oncogenesis25,26. The oncogenic property of H19 is also attributed to its full-length processed transcript that targets PRC2 (through binding to EZH2, the histone lysine methyltransferase component of PRC2) to genes that promote cancer metastasis27. In addition to these nuclear functions, H19 directly binds to the RNA-binding protein K homology-type splicing-regulatory protein in the cytoplasm to control myogenic differentiation28. Further, H19 acts as a molecular sponge for microRNA let-7, contributing to the regulation of muscle differentiation29, glucose metabolism16, tumour metastasis30 and endometrium development21.
In this report we show that H19 binds to SAHH and inhibits its function both in vivo and in vitro. This interaction prevents SAHH from hydrolysing SAH that blocks DNA methylation by DNMT3B at numerous genomic loci. This differs from what has been described before for other lncRNAs. We propose that this novel epigenetic regulatory mechanism may underlie the DNA methylation dynamics associated with development and diseases and that this mode of regulation may extend to other cellular components.
SAHH interacts with H19 in ribonucleoprotein complexes
In search of possible new functions of H19, we performed RNA affinity chromatography using an S1 aptamer-tagged H19 (pH19-S1; untagged pH19 or S1 tag only as negative controls)29 to identify H19-associated protein components (Fig. 1a). The indicated plasmids were each transfected into HEK293 cells that do not express endogenous H19. Purified ribonucleoproteins (RNPs) were resolved using SDS–PAGE, followed by Coomassie blue staining. A protein band with a molecular size of ∼48 kDa that was specific to pH19-S1 (Fig. 1b, left lane marked with a red arrow) was cut out and subjected to protein mass spectrometry analysis. A number of proteins were identified including SAHH, nuclear factor 45, propionyl-CoA carboxylase, methylcrotonoyl-CoA carboxylase, mitochondrial elongation factor Tu (EF-Tu), creatine kinase B-type, 40S ribosomal protein SA, multifunctional protein ADE2 isoform 2 and heterogeneous nuclear RNP D. We decided to focus on SAHH for several reasons. First, SAHH belongs to a large family of proteins that use NAD(P)+/NAD(P)H as cofactors via the dinucleotide-binding Rossmann-fold (a protein structural motif that binds nucleotides, especially the cofactor NAD)8. Second, a dozen enzymes harbouring the Rossmann-fold have been reported to bind polyadenylated RNAs in HeLa cells31. Third, the Rossmann-fold is an RNA-binding domain for both glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) and mediates their binding to AU- and U-rich RNA elements32,33. Finally, SAHH is the only mammalian enzyme capable of breaking down SAH, a potent product inhibitor of most SAM-dependent transmethylation reactions.
Western blot analysis of affinity-purified RNPs revealed association of SAHH with pH19-S1 but not with pH19 (Fig. 1c, top blot, compare lane 3 with lane 4). The RNA-binding protein HuR, previously shown to bind H19 (ref. 24), was also in complex with pH19-S1 under the same conditions (middle blot, lane 4), while beta-tubulin was not (bottom blot, lane 4). Taken together, these results supported the notion that the SAHH–H19 interaction was specific. Next, we performed RNA immunoprecipitation (RIP) experiments using a monoclonal antibody specific to SAHH with myotubes derived from mouse myoblasts to determine whether SAHH associates with endogenous H19 Both H19 and SAHH were predominantly localized to the cytoplasm of the myotubes (Supplementary Fig. 1). We observed a nearly eightfold enrichment of H19 in SAHH-containing RNPs relative to control IgG immunoprecipitates (Fig. 1d, left column), whereas GAPDH mRNA, expressed at approximately fourfold higher level than that of H19 (Fig. 1e), did not detectably associate with the SAHH-containing RNPs (Fig. 2e, right column). The specificity of the monoclonal SAHH antibody was confirmed using RIP and western blot analysis (Fig. 1f). As expected, we observed preferential enrichment of H19 in HuR-containing RNPs using a polyclonal HuR antibody under the same conditions (Supplementary Fig. 2). Collectively, we concluded that SAHH interacts with H19 in RNPs in both human and mouse cells.
H19 knockdown activates SAHH
What could be the functional significance of the SAHH–H19 interaction? We hypothesized that binding to H19 might interfere with SAHH’s ability to hydrolyse SAH to homocysteine and adenosine. To test this possibility, we used the well-characterized, imprinted Igf2-H19-Nctc1 gene locus in mouse skeletal muscle cells as a model system. The regulation of expression of these genes requires a shared enhancer that is located 20 kb downstream of H19 (or 100 kb downstream of Igf2)34. This enhancer functions in an unique manner in that it needs both a short core element of ∼300 bp (called core muscle enhancer, or CME) and transcription of the lncRNA-encoding gene Nctc1 within the same enhancer region35 (Fig. 1g). The CME resides within the gene body of Nctc1 in the second intron and is 7 kb downstream of the Nctc1 promoter. In adult muscle cells where Nctc1 has lost its imprinting36, activation of the Nctc1 promoter by CME has a negative impact on H19 expression. Promoter competition (the Nctc1 promoter recruits RNA polymerase II (RNAP) for its own transcription at the expense of activation of the H19 promoter) has been proposed as a possible underlying mechanism36. Indeed, in myotubes differentiated in vitro from mouse myoblasts Nctc1 expression was inversely correlated with that of H19. Consistent with the promoter competition model, association of RNAP with Nctc1 was also inversely correlated with H19 transcriptional activation36. Intriguingly, the CME contains a 219-bp CpG island with unknown function. We decided to use this well-characterized myotube system, where a negative impact of Nctc1 promoter activity on H19 transcription has been demonstrated36, to test the hypothesis that the SAHH–H19 interaction may affect CME methylation, which in turn influences the transcriptional activity of Nctc1 and H19.
Thus, we downregulated H19 using an H19-specific short interfering RNA (siRNA; siH19 (refs 16, 29)) in myotubes differentiated from mouse myoblasts, followed by in vivo SAHH activity assessment using homocysteine as a readout37. When the H19 level was reduced to ∼20% of the control (Fig. 2a, left column) without significantly affecting the level of SAHH mRNA (right column), an ∼20% increase in SAHH activity was observed (Fig. 2b). These results supported the view that H19 association inhibits SAHH’s ability to hydrolyse SAH, a strong inhibitor of SAM-dependent methyltransferases including DNMTs. We hypothesized that increased SAHH activity would activate DNMTs, which otherwise would be inhibited by SAH, leading to increased gene methylation. Indeed, we observed a 30% increase in a differentially methylated region (DMR) within the CME as determined by quantitative methylation-specific PCR (QMSP) analysis (Fig. 2c). The PCR primers were designed to cover this DMR based on our single-nucleotide resolution genome-wide DNA methylation analysis (Fig. 2d, and see below). Primers that cover another DMR (DMR-2) of CME showed similar results (Supplementary Fig. 3). Next, we wanted to test whether DNMT3B might be responsible for this increased methylation. It was previously reported that in human skeletal muscle cells the enzymatic activity (but not the protein level) of DNMT3B increased in response to free fatty acids, resulting in promoter hypermethylation of PGC-1a (ref. 38). Further, recent genome-wide DNA methylome studies revealed a strong association of DNMT3B with gene body methylation and its positive correlation with gene expression1,39. Thus, CME methylation was evaluated in the presence of double siRNA knockdown. In the H19/Dnmt3b double knockdown group, Dnmt3b was silenced by ∼40% at the RNA (Fig. 2e, right column) and ∼70% at the protein levels (Fig. 2f, top blot). While H19 single knockdown expectedly increased CME methylation (Fig. 2g, compare middle bar with left bar) without altering the DNMT3B protein level (Fig. 2f, top blot, compare middle lane with left lane), the double knockdown restored methylation to the control level (Fig. 2g), suggesting that DNMT3B contributed to increased CME methylation induced by H19 knockdown. A second siRNA (siDnmt3b-2) targeted to a different region of Dnmt3b produced similar results (Supplementary Fig. 4), confirming the specificity of the Dnm3b siRNA effects. Further, we carried out chromatin immunoprecipitation (ChIP) analysis using a DNMT3B antibody shown to be highly specific for DNMT3B in a genome-wide ChIP study1. Results revealed no significant change in DNMT3B occupancy at the DMR when H19 was downregulated (Fig. 2h), although a readily detectable change in RNAP association with Nctc1 was observed under the same conditions (see below). These results suggested that it was the activity and not the chromatin residence of DNMT3B that was responsible for the methylation change. This result is in line with a previous report showing that a change in the enzymatic activity of DNMT3B alone was sufficient to induce hypermethylation of PGC-1a in human skeletal muscle cells38. Collectively, these results suggested that reducing H19 level de-represses SAHH and enables it to act on SAH, thereby relieving inhibition of DNMT3B by SAH and allowing DNMT3B to methylate CME.
CME methylation correlates with enhanced Nctc1 transcription
To determine the effect of CME methylation on Nctc1 transcription, we performed ChIP analysis using an anti-Ser-5(P)-RNAP antibody that specifically recognizes activated RNAP as previously described35,36. We compared binding of activated RNAP to Nctc1 between control siRNA (siCon)- and siH19-transfected myotubes to assess relative transcription activity of Nctc1 (refs 35, 36). We observed an approximately fourfold enrichment in RNAP at Nctc1 in siH19- versus siCon-transfected myotubes (Fig. 2i), suggesting an increase in Nctc1 transcription that was further supported by the concomitant increase in the Nctc1 RNA level (Fig. 2j). This positive correlation between CME methylation and Nctc1 transcription was not surprising because increased gene body methylation has been associated with increased transcription1,3,39,40. We further noted a significant decrease in RNAP association with H19 in siH19-transfected myotubes (Fig. 2i, middle column, compare right green bar with left green bar). These results recapitulated the previously reported observation showing an inverse relationship of transcriptional activity between Nctc1 and H19 (ref. 36) and suggested a novel functional role of CME methylation in the regulation of Nctc1 and H19.
SAHH is required for H19-dependent CME methylation change
To provide further evidence that increased CME methylation induced by H19 knockdown was indeed mediated by SAHH, double knockdown experiments using a Sahh-specific siRNA10 were carried out. In the H19/Sahh double knockdown cells, Sahh was silenced by ∼60% at both the RNA (Fig. 3a, right column) and protein levels (Fig. 3b, top blot). While H19 single knockdown increased methylation, H19/Sahh double knockdown abrogated this effect (Fig. 3c). The abrogation effect was also observed when a pharmacological SAHH inhibitor D-Eritadenine (DEA; Supplementary Fig. 5)41,42 was used (Fig. 3c). These results further supported the notion that SAHH is required for H19-mediated CME methylation change.
As increased CME methylation following H19 knockdown correlated with increased Nctc1 transcription (Fig. 2g–j), we predicted that H19 and Sahh double knockdown would reverse this effect, given that increased CME methylation was dependent on SAHH activation (Fig. 3c). Consistent with our earlier observations (Fig. 2i, left column; and Fig. 2j, right column), H19 single knockdown increased RNAP association with Nctc1 (Fig. 3d, left column, compare middle green bar with left green bar) with a concomitant increase in the Nctc1 RNA level (Fig. 3e, compare middle bar with left bar). In the H19 and Sahh double knockdown cells, RNAP association with Nctc1 was significantly reduced compared with that in the H19 single knockdown cells (Fig. 3d, left column, compare right green bar with the middle green bar), and there was a decrease in the Nctc1 RNA level as well (Fig. 3e). Moreover, the inverse relationship of RNAP association between Nctc1 and H19 was lost in the double knockdown cells (Fig. 3d, compare between the left and middle columns). Collectively, these results strongly suggested that H19 induced CME methylation change through the action of SAHH, which in turn affected the transcription of Nctc1 and H19.
U-rich element binding inhibits SAHH activity in vitro
To further delineate the molecular nature of SAHH–H19 interaction, we took an in vitro approach to map binding sites of SAHH on H19. Both GAPDH and LDH bind to AU- and U-rich RNA elements via the Rossmann-fold32,33. SAHH has a Rossmann-fold that binds cofactor NAD+, which is required for maintaining its quaternary structure and catalytic function8. We hypothesized that SAHH may bind U-rich elements (URE), as we noticed stretches of UREs flanked by C or G near the 3′-end of both human and mouse H19 (Fig. 4a). To test this hypothesis, we performed electrophoretic mobility shift assays (EMSAs) using purified recombinant human SAHH protein (rSAHH) and 3′-end biotin-labelled H19 RNA fragments. At low rSAHH concentrations, only one complex (complex 1) formed with both human (hURE) and mouse (mURE) fragments (Fig. 4b, top two panels on the left). As rSAHH concentration rose, an additional complex (complex 2) appeared, suggesting simultaneous binding of more than one molecule of rSAHH to multiple U-rich sequences. We estimated the Kd values of rSAHH binding to the human and mouse UREs to be 0.44 and 0.46 μM, respectively (Fig. 4b, bottom panel), similar to the Kd value of LDH for the granulocyte–macrophage colony-stimulating factor RNA AU-rich element, which was reported to be 0.5 μM (ref. 33). The apparently slightly lower Kd value of hURE was also reflected by competition experiments showing that unlabelled hURE competed better for binding to rSAHH than the unlabelled mURE (Fig. 4c, left two panels). A non-U-rich fragment (hNSE) randomly chosen from human H19 failed to efficiently compete for rSAHH binding (Fig. 4c, third panel), which was consistent with its poor rSAHH-binding affinity (Fig. 4b). Further, the poly(U) ribohomopolymers exhibited the highest activity in reducing complex formation (Fig. 4c, fourth panel). Together, these results showed that purified rSAHH was capable of direct binding to UREs in both human and mouse H19 in vitro.
As H19 binds and inhibits SAHH activity in vivo (Figs 1c,d and 2b), we tested effects of H19 fragments on the ability of rSAHH to hydrolyse SAH in vitro. Both hURE and mURE inhibited the hydrolytic activity of rSAHH in a dose-dependent manner, whereas hNSE did not (Fig. 4d). This was in line with the observation that both UREs had significantly higher affinity for rSAHH than hNSE (Fig. 4b,c). As expected, poly(U) also efficiently inhibited rSAHH activity (Fig. 4d). Combined with our in vivo data (Figs 1c,d and 2b), these results strongly support our hypothesis that SAHH binding to H19 interferes with its ability to hydrolyse SAH in vivo.
H19-dependent SAHH inhibition exerts global effects
As SAHH can potentially affect SAM-dependent methyltransferases other than DNMT3B, one would predict that H19 knockdown would lead to global DNA methylation changes. Methylation at a particular cytosine residue within a gene locus is influenced both by the activity of DNMTs and by other epigenetic marks that affect their accessibility1,2,3. SAHH activity change could not only directly affect the activity of DNMTs, but also other epigenetic marks, which in turn might indirectly affect gene methylation. Further, not all methyltransferases display an equal sensitivity to SAHH inhibition8. Thus, increased SAHH activity as a result of H19 knockdown is expected to produce three different outcomes: some genomic loci would become hypermethylated; some hypomethylated; and some would not change, relative to control knockdown.
As a proof-of-principle that H19 modulates gene methylation through SAHH, we performed global DNA methylation studies to identify genes whose methylation might be affected in a way similar to that of Nctc1. Mytotubes were transfected with siH19 (or siCon as a control), and DNA was extracted 48 h later and subjected to genome-scale DNA methylation mapping using the platform of an improved version of Reduced Representation Bisulfite Sequencing. This platform offers detection of —three to four million unique CpG sites, allowing >85% coverage of all annotated CpG islands and >80% of all gene promoters for a maximal amount of methylation data. It allows the identification and analysis of DMRs between samples at single-nucleotide resolution. As expected, following H19 knockdown we observed extensive genome-wide methylation pattern changes relative to siCon cells, with some genes showing increased methylation, others showing decreased methylation and a third group with no significant change (Supplementary Fig. 6). We hypothesized that in the group of genes showing increased methylation, some were likely affected by increased activity of DNMT3B as a direct result of SAHH activation. To test this possibility, we selected five genes showing strong hypermethylation with siH19 (Supplementary Data 1). Since SAHH dysfunction is associated with human diseases8,10,11, we selected genes having important cellular functions or implicated in diseases. Bmp8b (bone morphogenetic protein 8b) has been reported to act as a signalling molecule in energy balance regulation in both brown adipocytes and neurons, and Bmp8b null mice exhibit decreased rate of metabolism and impaired thermogenesis43. Casp2 (Caspase 2) is a member of the caspase family that mediates cellular apoptosis through the proteolytic cleavage of specific protein substrates44. In addition to its well-defined role in cell death, Casp2 has been implicated in neurodegenerative diseases, tumorigenesis, metabolism and aging44. Cdt1 (chromatin licensing and DNA replication factor 1) is a component of the prereplicative complex that assembles on genomic DNA at origins of replication. Mutations in this gene have been associated with growth failure in primordial dwarfism45. Foxa2 (forkhead box A2) is a DNA-binding transcription factor essential for the development of endoderm-derived organs including the liver and pancreas. Foxa2 has been implicated in blood glucose homeostasis by controlling the expression of multiple genes in pancreatic beta-cells46. Setd2 (SET domain containing 2) is a member of the SAM-dependent histone lysine methyltransferase family (which also includes EZH2, a component of PRC2) known to be important for chromatin modification2,47. SETD2 interacts with the Huntington’s disease (HD) protein Huntingtin and has been implicated in the pathogenesis of HD, a neurodegenerative disorder characterized by loss of striatal neurons48.
To determine whether the increased methylation in these genes as revealed by genome-wide analysis was SAHH-dependent, myotubes were transfected with siH19 or siCon, with or without co-transfection of siSahh or treatment of SAHH inhibitor DEA. QMSP analysis was carried out 48 h post transfection using primers that specifically amplify a single DMR of each respective gene (Fig. 5a). While H19 knockdown increased DMR methylation, its combination with siSahh or DEA rescued methylation to the level of the control (Fig. 5b). These results strongly suggested H19-mediated, SAHH-dependent regulation of methylation at these sites, thus validating our genome-wide data. To further address whether DNMT3B might contribute to the increased methylation, H19/Dnmt3b double knockdown experiments were carried out, followed by QMSP analysis. As shown in Fig. 5c, siH19 in combination with either Dnmt3b siRNA was able to partially or fully restore methylation to the level of the siCon control. The partial rescue by the Dnmt3b siRNAs suggested that other DNMTs may contribute to the methylation of these sites, which warrants future investigation. It is noteworthy that, while a single DMR methylation change may seem small, the combined effects from multiple DMRs in a single gene (Supplementary Table 1 and Gene Expression Omnibus (GEO) accession number GSE73014) could potentially be synergistic, leading to bigger biological effects.
Next, DNMT3B ChIP analysis was conducted following siRNA transfection (Fig. 6a). While no DNMT3B association was detected at the DMRs of Cdt1 and Setd2, for the remaining three genes tested, no change in DNMT3B occupancy at the respective DMRs was observed following H19 knockdown (Fig. 6b). These results supported the notion that the H19 knockdown-induced increase in methylation was due to changes in DNMT3B activity rather than its chromatin association.
H19 regulates gene expression via multiple mechanisms, both in the nucleus and in the cytoplasm. Thus, H19 knockdown could alter its nuclear interaction with methyl-CpG-binding domain protein 1 and/or EZH2 to affect gene transcription23,27. In the cytoplasm, H19 knockdown could change the dynamic association of K homology-type splicing-regulatory protein with its target mRNAs, leading to their stability changes28. The mRNA levels of genes targeted by let-7 could also be affected, as H19 acts as a molecular sponge for let-7 (ref. 29). Finally, H19 could modulate transcription by affecting gene methylation through interaction with SAHH (this report). Thus, the effects of H19 knockdown on genome-wide transcript levels would represent a summation of contributions from the different mechanisms outlined above as well as from other yet unknown mechanisms. Consistent with this view, our RNA-sequencing (RNA-seq) analysis revealed profound changes in transcript profiles between siCon- and siH19-transfected myotubes (Supplementary Data 2 and GEO accession number GSE73014). While a number of these are consistent with alterations in DNA methylation profiles, the multiplicity of H19 functions does not at this time allow definitive mechanistic connections to be established.
This study uncovers a novel regulatory circuit of gene methylation dictated by the interaction between H19 and SAHH. Using the Igf2-H19-Nctc1 gene locus in mouse muscle cells as a model, we demonstrate that binding of SAHH to H19 interferes with its ability to hydrolyse SAH, which is a potent product inhibitor of SAM-dependent methyltransferases. This leads to decreased DNMT3B-mediated methylation within the Nctc1 gene body and subsequently reduced transcriptional activity of the Nctc1 promoter. We show that UREs in H19 that display preferential binding to SAHH also inhibit the catalytic activity of SAHH, suggesting that the basis for this preferential interaction is recognition of the UREs. Further, we demonstrate that this H19–SAHH-dependent regulation occurs at other genomic loci, suggesting global effects of this regulation. On the basis of these findings, we propose the model illustrated in Fig. 6c. To our knowledge, this represents the first case in which a single lncRNA acts in trans to alter the epigenetic landscape in a genome-wide manner.
Importantly, our findings offer novel insights into DNA methylation regulation associated with development and pathological conditions. Specifically, our results suggest that the enzymatic activity of chromatin-bound DNMT3B might be subjected to modification by H19 through the H19/SAHH pathway. Interestingly, DNMT3B (but not DNMT1) was shown to be required for restoring demethylated genomic regions induced by the methylation inhibitor 5-Aza-CdR (ref. 39). Further, a recent genome-scale study comparing DNMT occupation with DNA methylation patterns showed that a fraction of gene loci bound by DNMTs does not overlap with methylation and that the number of such loci changes dramatically on cell differentiation1. It has been proposed that loci bound by DNMTs, but which are not methylated, may be primed for later de novo methylation events that are associated with cell pluripotency and differentiation states1. It is possible that the bound DNMTs are inactive because of inhibition (by yet unknown mechanisms), which is removed as cell states change. H19 expression is both temporally and spatially regulated during development, and its aberrant expression has been linked to human genetic disorders and cancer14,22. It is tempting to postulate that the enzymatic activity of DNMTs might be modulated in response to developmental cues and pathological conditions and that the H19–SAHH axis might be a functional link underlying these regulations.
It has become increasingly evident that the relationship between methylation and gene expression is far more complex than previously thought. Unlike the classic models linking promoter methylation to gene silencing and gene body methylation to expression, emerging models posit that the correlation between methylation and gene expression is genomic context-dependent1,3. Factors such as distance of CpGs relative to the transcription start site, their residence in CpG islands, promoters, enhancers or gene bodies as well as combinations of any of these can positively or negatively affect gene expression. Thus, it is not merely the sum or density of all methylated CpGs (which were used to label a gene as being ‘hyper’ or ‘hypo’ methylated) but rather the combinations of the various factors described above as well as of other yet unknown factors that determine the outcome on gene expression. Our studies reveal that H19 regulates methylation at many genomic sites through modulating the activity of SAHH. Further investigation will certainly unravel a highly complex and context-dependent nature of this regulation. Depending on cell/tissue types, developmental stages and disease states, the biological end points of this H19/SAHH-mediated regulation of gene methylation are likely to be diverse. Curiously, the brain expresses very low or undetectable levels of H19 (ref. 18) while accumulating uniquely high levels of DNA hydroxymethylation (5-hydroxymethylcytosine) during postnatal development49. Hydroxymethylation occurs through oxidation of the methyl group of 5-methylcytosines by TET enzymes, and this epigenetic modification is thought to be important for neuronal differentiation and function49,50,51. As hydroxymethylation has been implicated in the active DNA demethylation mechanism, it remains to be determined whether the activity of SAHH in the brain might be significantly lower or the activity of SAHH might be subjected to regulation by non-H19-mediated mechanisms. Finally, as SAM-dependent methyltransferases methylate other cellular components besides DNA, our findings open up new avenues for future investigations of other cellular components that might be regulated by the H19/SAHH-dependent mechanism.
Reagents and plasmids
Mouse monoclonal anti-SAHH (Santa Cruz Biotechnology, sc-271389), rabbit polyclonal anti-SAHH (Proteintech, 10757-2-AP), mouse monoclonal anti-HuR (Santa Cruz, sc-5261), rabbit polyclonal anti-HuR (Proteintech, 11910-1-AP), rabbit polyclonal anti-DNMT3B (Novus, NB300–516), rabbit polyclonal anti-RNAP CTD repeat YSPTSPS (phospho S5; Abcam, ab5131), rabbit polyclonal anti-β-tubulin (Abcam, ab6046), mouse monoclonal anti-β-actin (Abcam, ab8226), mouse pre-immune IgGs (Chemicon, PP54) and rabbit pre-immune IgGs (Thermo Scientific, Prod #1862244) were purchased. SiRNAs specific for mouse H19 (siH19, 4390816/n253566), SAHH (siSahh, AM16708/72248), Dnmt3b (siDnmt3b, AM16708/161533; siDnmt3b-2, 4390771/S65080) and negative siCon (AM4636) were purchased from Ambion/Life Technologies. The SAHH inhibitor DEA (sc-207632) was purchased from Santa Cruz. To construct pH19, PCR was carried out using human term placental cDNA as a template with forward 5′-aaggaaaaaagcggccgcAGCAGGGTGAGGGAGGGGGTG-3′ and reverse 5′-cgcggatccGTAACAGTGTTTATTGATGATGAGTC-3′ primers. The lower-case letters represent restriction enzyme sites for NotI and BamHI, respectively, and the upper-case letters are complementary to H19 sequence. The resulting 2.6-kb-long PCR product was inserted into pFLAG-CMV-2 (Sigma) opened with NotI and BamHI. To make pH19-S1, an annealed oligonucleotide fragment containing a 44-nt-long S1 sequence (5′-ACCGACCAGAATCATGCAAGTGCGTAAGATAGTCGCGGGCCGGG-3′) was cloned into pH19 at its 3′-end opened with BamHI. pS1 was made by inserting the S1 sequence into pFLAG-CMV-2 (Sigma) opened with NotI and BamHI.
Cell culture and transfection
HEK293 cells (ATCC, CRL-1573) were cultured using standard protocols provided by the ATCC. Undifferentiated mouse C3H myoblasts (Sigma-Aldrich, 91031101-iVL) were maintained in growth medium (GM; DMEM, Gibco, 11965-092, supplemented with 10% fetal bovine serum, heat-inactivated, 1% penicillin/streptomycin, 1% L-glutamine and 1-mM sodium pyruvate). To prepare for differentiation, cells were seeded at a density of 1.6 × 105 or 1.0 × 104 cells per well in GM in 6- or 48-well plates, respectively. Differentiation was initiated 2 days later when cells became confluent by replacing GM with differentiation medium containing 2% horse serum in place of 10% fetal bovine serum. The medium was changed every other day until transfection, which was performed on days 3–4 after initiation of differentiation.
For cell transfection, mytotubes were washed once with pre-warmed OPTI-MEM immediately before addition of transfection cocktails. To prepare transfection cocktails for each well of six-well plates, 250 pmol of siCon or siH19 (with a stock solution of 5 μM) was mixed with 300 μl of OPTI-MEM by gentle pipetting. In parallel, 12.5 μl of Lipofectamine 2000 was diluted in 300 μl of OPTI-MEM by gentle pipetting. After 5-min incubation at room temperature, the two were combined by gentle pipetting. Following incubation at room temperature for 25 min, the resulting cocktail (600 μl) was directly applied to myotubes that were pre-washed with OPTI-MEM. After overnight incubation in a tissue culture incubator, the cocktail was replaced with fresh differentiation medium. Forty-eight hours later, RNA and protein were extracted for analysis.
RNA in situ hybridization and SAHH immunofluorescence
Undifferentiated myoblasts were seeded in μ-Slide eight-well plates (Ibidi cat. no. 80826) at ∼2 × 104 cells per well, and differentiation was initiated as described above. H19 RNA FISH experiments were carried out using the RNAscope fluorescent Multiplex system (Advanced Cell Diagnostic Inc.) according to the manufacturer’s instructions. The protocol involves proteinase K treatment to remove proteins including nucleases. The system included the following components: Probe-Mm-H19-C3 (P/N: 423751-C3, L/N: 14241A; custom-designed specific for mouse H19), Blank-C1 (P/N: 300041; L/N: 14132A), 3-Plex Negative Control probe (P/N: 320371; L/N: 14105A), Pretreatment Kit-FL FF (P/N: 320842; L/N: 14099A) and Detection Kit-FL (P/N: 320851; L/N: 14098A). For SAHH immunostaining, myotubes were washed briefly with TBS (20 mM Tris-HCl, pH 7.4, 225 mM NaCl), fixed with 3% paraformaldehyde/TBS for 20 min, permeabilized with 1% SDS/TBS for 5 min and blocked with 10% BSA/0.1% goat serum/TBS for 1 h. Cells were then incubated with polyclonal anti-SAHH antibody at a dilution of 1:100 for 1 h, washed with TBS and then incubated with Alexa-488 secondary antibody (1:500 dilution, Invitrogen, Grand Island, NY) for 1 h. After washing with TBS, cells were mounted with mounting medium containing 4,6-diamidino-2-phenylindole (Vector Lab, Burlingame, CA). Images were obtained under the fluorescence microscopy (Axiovert S 100; Carl Zeiss, Oberkochen, Germany).
RNP affinity purification and protein identification
HEK293 cells were transfected with pH19-S1, pH19 or pS1 in a 25-cm plate scale and harvested 48 h later by manual scraping and pelleted by centrifugation. After washing twice in ice-cold PBS, cell pellet was resuspended in 1.2 ml of ice-cold gentle lysis buffer (GLB) (10 mM Tris-HCl, pH 7.5; 10 mM NaCl; 10 mM EDTA; 0.5% Triton X-100; 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 × proteinase inhibitor cocktail (CalBiochem, 539137); 1 mM dithiothreitol (DTT) and 1 × RNase inhibitor (Roche, 10412600)) in a 1.5-ml eppendorf tube and incubated on ice for 20 min. Cell lysate was centrifuged to remove insoluble materials. The lysate was precleared by incubation at 4 °C for 1.5 h with 40 μl of avidin agarose beads (Pierce, 20219) with NaCl added to a final concentration of 150 mM. The cleared lysate was mixed with 40 μl of streptavidin beads (packed volume, Sigma, S1638-5ML) and the tube was rotated at 4 °C for 3 h. The beads were collected and washed with 1 ml of ice-cold GLB plus (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 10 mM EDTA; 0.5% Triton X-100) five times by rotating the tube at 4 °C for 3 min each. The purified RNPs were eluted from the beads in 20 μl of 2 × SDS sample buffer by heating at 100 °C for 5 min and resolved by 10% SDS–PAGE. Following Commassie staining, the protein band at 48 kDa in the pH19-S1 lane was excised and submitted for mass spectrometry analysis by ProtTech Inc. (Norristown, PA 19403).
To prepare antibodies, 20 μl of protein A Sepharose beads were incubated with 20 μg of monoclonal anti-SAHH antibody or 20 μg of mouse pre-immune IgG in 500 μl IP buffer (0.5% Triton X-100, 200 mM NaCl, 10 mM Tris-HCl at pH 7.5 and 10 mM EDTA) at 4 °C overnight. The next day, the beads were washed three times with IP buffer and kept on ice until used. To prepare cell lysates, myotubes (from one well of a six-well plate) were harvested and cell pellets resuspended in 600 μl of freshly prepared lysis buffer (0.5% Triton X-100, 10 mM NaCl, 10 mM Tris-HCl at pH 7.5, 10 mM EDTA, 0.5 mM PMSF, 1 mM DTT, 1 × protease inhibitor cocktail (Calbiochem) and 400 units per ml RNase inhibitor). The suspensions were incubated on ice for 20 min. After removing insoluble materials by centrifugation, lysates were precleared using 10 μl of protein A sepharose (NaCl was added to a final concentration of 200 mM), followed by addition of yeast tRNA (Ambion) to a final concentration of 40 μg ml−1. The cleared lysates were transferred to tubes containing antibody or pre-immune IgG-coated beads, and IP was carried out by rotating the tubes at 4 °C for 3 h. Following IP, the beads were washed five times with IP buffer by adding 1 ml of the buffer and rotating the tube at 4 °C for 2 min each time. RNA was extracted from the beads using the PureLink RNA Mini Kit (Ambion, cat. no. 12183018A). Reverse transcription was performed in a 40-μl reaction volume using the Bio-Rad iScript cDNA synthesis kit, followed by quantitative PCR (qPCR).
Genomic DNA extraction
Genomic DNA was isolated using Quick-gDNA MicroPrep (Zymo, D3021) according to the manufacturer’s instructions.
RNA extraction and RT–qPCR
Total RNAs were extracted from cells using the PureLink RNA Mini Kit (Ambion, cat. no. 12183018A). cDNA was synthesized using the Bio-Rad iSCRIPT kit (1725122) in a 20-μl reaction containing 100–500 ng of total RNA. Quantitative real-time PCR (RT–qPCR) was performed in a 15-μl reaction containing 0.5–1 μl of cDNA using iQSYBRGreen (Bio-Rad) in a Bio-Rad iCycler. PCR was performed by initial denaturation at 95 °C for 5 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. Specificity was verified using melting curve analysis and agarose gel electrophoresis. The threshold cycle (Ct) values of each sample were used in the post-PCR data analysis. The RT–PCR primers are listed in Supplementary Table 1.
Western blot analysis
Cell pellets were quickly lysed in five volumes of 2 × SDS sample buffer heated at 100 °C for 5 min, with occasional vortexing. Five to ten microlitres of homogenized samples were loaded on 10% SDS gel, followed by western blot analysis. The linear dynamic range of each protein of interest was determined by serial dilutions. Bands on western blot gels were quantified using ImageJ. Uncropped blots of Fig. 1c are shown in Supplementary Fig. 7.
Genomic DNA was extracted from myotubes in one well of six-well plates using Quick-gDNA MicroPrep. Fifteen microlitres of water were used to elute DNA from each column. For bisulfite treatment, 400–500 ng of DNA was used for each column using the EZ DNA Methylation-Gold Kit (Zymo, D5006). RT–qPCR was performed in a 15-μl reaction containing 1 μl of the eluant using iQSYBRGreen (Bio-Rad) in a Bio-Rad iCycler. The PCR primers (Supplementary Table 2) for methylated DNA were used at a final concentration of 0.3 μM in each PCR reaction. PCR was performed by initial denaturation at 95 °C for 5 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. Specificity was verified using melting curve analysis and agarose gel electrophoresis. The Ct values of each sample were used in the post-PCR data analysis. Albumin DNA was used as loading controls for all QMSP normalization.
In vivo SAHH activity assay
The experiments were performed in a 96-well scale using the Mouse Homocysteine (Hcy) ELISA Kit (Mybiosource, MBS260152) that allows quantitative measurement of homocysteine concentration in cell extracts, according to the manufacturer’s instructions. The concentration of homocysteine in cell extracts was used as a readout for in vivo SAHH activity37, as SAHH hydrolyses SAH to homocysteine and adenosine. Briefly, myotubes were washed with cold PBS and lysed on plate in 200 μl of lysis buffer (40 mM hexadecyltrimethylammonium bromide, 75 mM Tris-HCl, pH 8.0, 1 M NaCl, 15 mM EDTA). The lysate was cleared of insoluble materials by centrifugation at 15,000g at 4 °C for 15 min. Immediately following the centrifugation, 100 μl of the supernatant was collected and used for SAHH activity measurement. The absorbance of the samples was determined using a FilterMax F3&F5 Multi-Mode Microplate Reader (Molecular Devices). A serial dilution of mouse Hcy was included in each assay to obtain a standard curve. The assay was performed in triplicate. The concentrations of DNA and RNA extracted from parallel wells were used as loading controls for SAHH activity normalization.
These experiments were performed in a six-well plate scale using the Pierce Agarose ChIP Kit (Thermo Scientific, 26156) according to the manufacturer’s instructions with minor modifications. Briefly, myotubes were detached from plates in 0.25% Trypsin-EDTA and transferred to a 1.5-ml tube. Crosslinking was performed in 1% formaldehyde at room temperature for 10 min, and the reaction was stopped by glycine. ChIPs using anti-Ser-5(P)-RNAP or anti-DNMT3B antibodies (or rabbit pre-immune IgGs as a negative control) were carried out overnight at 4 °C. Levels of ChIP-purified DNA were determined with RT–qPCR (see Supplementary Table 3 for primer sequences). The relative enrichments of the indicated DNA regions were calculated using the Percent Input Method according to the manufacturer’s instructions.
Production of RNA fragments for in vitro analyses
Zymo Taq DNA polymerase (Zymo Research, E2001) was used to amplify hURE (128 nucleotide (nt)), mURE (122 nt) and hNSE (131 nt) using plasmid DNA containing human29 or mouse (accession no. NR_001592) H19 sequences as PCR templates. All forward primers contained a T7 promoter sequence (Supplementary Table 4). The PCR products were purified using Zymo DNA clean and concentrator kit (Zymo Research, D4003) and used as templates for subsequent in vitro transcription. RNA fragments for EMSA and in vitro rSAHH activity analysis were generated by in vitro transcription using the T7 MEGAscript Kit (Ambion, AM1334). The resulting RNA was lithium chloride precipitated and the quality of the RNA was confirmed using electrophoresis. The RNA 3′ End Biotinylation Kit (Thermo Scientific, 20160) was used to make 3′-end biotin-labelled RNA fragments, according to the manufacturer’s instructions. The biotin-labelled RNA fragments were extracted with phenol:chloroform and precipitated with 70% ethanol. Purified RNA fragments were aliquoted and stored at −80 °C until use.
Binding reactions were carried out in 20 μl containing 5 nM of 3′-end biotin-labelled RNA, together with indicated amounts of Escherichia coli-expressed, purified rSAHH, (Creative BioMart, AHCY-31342TH). Binding buffer contained 5 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 3% (v/v) glycerol, 100 mM NaCl, 1 mM DTT, 1 × proteinase inhibitor cocktail (CalBiochem, 539137) and 1 × RNase inhibitor (Roche, 10412600)). Before mixing with the rest of the components in the binding reaction, RNA was heated at 90 °C for 3 min, followed by immediate chill on ice until use. Binding reaction was conducted at 25 °C for 30 min. At the end of incubation, 5 μl of loading buffer was added and samples loaded on 4% native polyacrylamide gels (Bio-Rad mini protein gel size), which had been pre-electrophoresed at 4 °C for 60 min in 0.5 × Tris-borate-EDTA. Electrophoresis was carried out at 4 °C at 140 V for 75 min. Following electrophoresis, components in the gels were transferred to Amersham Hybond-N+ nylon membrane (GE Healthcare, RPN303B) in 0.5 × Tris-borate-EDTA at 400 mA for 38 min at 4 °C. The membrane was then crosslinked with ultraviolet light (254 nm) for 4 min at a distance of 0.5 cm. Signals were developed using LightShift chemiluminescent EMSA kit (Thermo Scientific, 89880) according to the manufacturer’s instructions.
For EMSA competition assays, rSAHH protein and labelled hURE RNA were added to a 20-μl reaction at final concentrations of 2 μM and 5 nM, respectively. Unlabelled hURE, mURE, hNSE and poly(U) (Sigma-Aldrich, P9528-10MG) were added at the indicated molar excess, followed by incubation and electrophoresis, as described above.
Band intensities of scanned films were quantified using the ImageJ software, and the data processed using the GraphPad Prism programme (Version 6.0f). The per cent bound RNA was determined as follows: [% bound complex=(bound probe−background)/(total probe−background) × 100]. All experiments contained a control reaction lacking rSAHH. Kd was calculated using nonlinear regression analysis performed with the Prism 6.0f software. Kd is the dissociation constant. Signals of complexes 1 and 2 were combined to generate probe-bound signals in Kd calculation.
In vitro rSAHH activity assays
These experiments were designed to test whether binding of H19 RNA fragments to rSAHH would inhibit rSAHH enzymatic activity in vitro. The experiments were performed using the Adenosylhomocysteinase Activity Fluorometric Assay Kit (Biovision, K807-100) according to the manufacturer’s instructions. This kit allows quantitative detection of adenosine concentration as a readout for rSAHH’s ability to hydrolyse SAH in vitro. Briefly, 2 mg of rSAHH was pre-incubated with unlabelled RNA fragments (preheated at 90 °C for 3 min and then chilled on ice before use) in AHCY assay buffer in a total volume of 20 μl at room temperature for 20 min. At the end of incubation, an additional 30 ml of AHCY assay buffer was added, followed by addition of 50 μl of reagents containing SAH. The resulting 100 μl reaction mixture was immediately subjected to absorbance reading using a kinetic mode in a FilterMax F3&F5 Multi-Mode Microplate Reader (Molecular Devices). In the final 100-μl reaction mixture, the concentration of rSAHH was 0.4 mM, and those of the RNA fragments were 0, 0.2 and 1 nM. Relative rSAHH activities are presented with those in the absence of the RNA fragments arbitrarily set as 1.
Methyl-MiniSeq library construction
Libraries were prepared from 200 to 500 ng of genomic DNA digested with 60 units of TaqαI and 30 units of MspI (NEB) sequentially and then extracted with Zymo Research DNA Clean & Concentrator-5 kit (Cat. no. D4003). Fragments were ligated to pre-annealed adapters containing 5′-methyl-cytosine instead of cytosine according to the Illumina’s specified guidelines (www.illumina.com). Adaptor-ligated fragments of 150–250 and 250–350 bp in size were recovered from a 2.5% NuSieve 1:1 agarose gel (Zymoclean Gel DNA Recovery Kit, Zymo Research Cat. no. D4001). The fragments were then bisulfite-treated using the EZ DNA Methylation-Lightning Kit (Zymo Research, Cat. no.D5020). Preparative-scale PCR was performed and the resulting products were purified (DNA Clean & Concentrator, Zymo Research, Cat. no.D4005) for sequencing on an Illumina HiSeq.
Methyl-MiniSeq Sequence alignments and data analysis
Sequence reads from bisulfite-treated EpiQuest libraries were identified using standard Illumina base-calling software and then analysed using a Zymo Research proprietary analysis pipeline, which is written in Python and used Bismark (http://www.bioinformatics.babraham.ac.uk/projects/bismark/) to perform the alignment. Index files were constructed using the bismark_genome_preparation command and the entire reference genome. The non_directional parameter was applied while running Bismark. All other parameters were set to default. Filled-in nucleotides were trimmed off when doing methylation calling. The methylation level of each sampled cytosine was estimated as the number of reads reporting a C, divided by the total number of reads reporting a C or T. Fisher’s exact test or t-test was performed for each CpG site, which has at least five reads coverage, and promoter, gene body and CpG island annotations were added for each CpG included in the comparison.
RNA-seq and data analysis
Mouse C3H myoblasts were maintained in six-well plates. Myotubes were transfected with siCon or siH19 in triplicates for 40 h following initiation of differentiation. Cells were harvested for RNA extraction 48 h post transfection using the Purelink RNA mini kit (Cat. no. 12183018A). RNA-seq libraries were prepared using the Illumina TruSeq Stranded Total RNA LT kit with Ribo-Zero Human/Mouse/Rat, setA (Cat. no. rs-122–2201) according to the sample preparation protocol. Briefly, 1 μg total RNA was subjected to Ribo-Zero depletion to remove rRNAs. The remaining RNA was purified, fragmented and primed with random hexamers for cDNA synthesis. After first and second cDNA synthesis, cDNA fragments were adenylated and then ligated to indexing adapters. The cDNA fragments were enriched by PCR, purified and then sequenced on an Illumina NextSeq500 using paired-end chemistry and 76-bp cycles. Sequences are available from the GEO with accession number GSE73014.
Illumina BaseSpace (https://basespace.illumina.com/)-embedding tools were used to analyse the RNA-seq data. TopHat Alignment 1.0.0 app was used to map sequencing reads to mm10 genome. Cufflinks Assembly & DE 1.0.0 app containing Cufflinks 2.1.1 and Cuffdiff 2.1.1 was applied to assemble mapped transcripts and calculate differential expression of genes and transcripts.
All data (unless otherwise indicated) are presented as mean±s.d. Statistical analyses were performed using the Statistical Package for the Social Science computer software version 17.0 (IBM SPSS Statistics, Chicago, IL, USA). The Student’s t-test was used to compare differences between quantitative variables. The Fisher’s exact text was used when appropriate, for comparing categorical variables (contingency tables). P values at 0.05 or smaller were considered significant.
Accession codes: RNA-seq and methylation profile data are available at the GEO under accession code: GSE73014.
How to cite this article: Zhou, J. et al. H19 lncRNA alters DNA methylation genome-wide by regulating S-adenosylhomocysteine hydrolase. Nat. Commun. 6:10221 doi: 10.1038/ncomms10221 (2015).
Gene Expression Omnibus
Jin, B. et al. Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. Cell Rep. 2, 1411–1424 (2012) .
Varier, R. A. & Timmers, H. T. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815, 75–89 (2011) .
Varley, K. E. et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 23, 555–567 (2013) .
Brenner, C. et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 24, 336–346 (2005) .
Guttman, M. & Rinn, J. L. Modular regulatory principles of large non-coding RNAs. Nature 482, 339–346 (2012) .
Cech, T. R. & Steitz, J. A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157, 77–94 (2014) .
Di Ruscio, A. et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 503, 371–376 (2013) .
Tehlivets, O., Malanovic, N., Visram, M., Pavkov-Keller, T. & Keller, W. S-adenosyl-L-homocysteine hydrolase and methylation disorders: yeast as a model system. Biochim. Biophys. Acta 1832, 204–215 (2013) .
Miller, M. W. et al. The mouse lethal nonagouti (a(x)) mutation deletes the S-adenosylhomocysteine hydrolase (Ahcy) gene. EMBO J. 13, 1806–1816 (1994) .
Leal, J. F. et al. S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis 29, 2089–2095 (2008) .
Baric, I. Inherited disorders in the conversion of methionine to homocysteine. J. Inherit. Metab. Dis. 32, 459–471 (2009) .
De Clercq, E. John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 24, 1395–1415 (2005) .
Wang, Y. et al. Regulation of s-adenosylhomocysteine hydrolase by lysine acetylation. J. Biol. Chem. 289, 31361–31372 (2014) .
Gabory, A., Jammes, H. & Dandolo, L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 32, 473–480 (2010) .
Dey, B. K., Pfeifer, K. & Dutta, A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev. 28, 491–501 (2014) .
Gao, Y. et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 42, 13799–13811 (2014) .
Ohlsson, R., Hedborg, F., Holmgren, L., Walsh, C. & Ekstrom, T. J. Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. Development 120, 361–368 (1994) .
Gabory, A. et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development 136, 3413–3421 (2009) .
Onyango, P. & Feinberg, A. P. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc. Natl Acad. Sci. USA 108, 16759–16764 (2011) .
Venkatraman, A. et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature 500, 345–349 (2013) .
Ghazal, S. et al. H19 lncRNA alters stromal cell growth via IGF signaling in the endometrium of women with endometriosis. EMBO Mol. Med. 7, 996–1003 (2015) .
Matouk, I. et al. The increasing complexity of the oncofetal h19 gene locus: functional dissection and therapeutic intervention. Int. J. Mol. Sci. 14, 4298–4316 (2013) .
Monnier, P. et al. H19 lncRNA controls gene expression of the Imprinted Gene Network by recruiting MBD1. Proc. Natl Acad. Sci. USA 110, 20693–20698 (2014) .
Keniry, A. et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell Biol. 14, 659–665 (2012) .
Tsang, W. P. et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31, 350–358 (2010) .
Wang, G. et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat. Genet. 45, 739–746 (2013) .
Luo, M. et al. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333, 213–221 (2013) .
Giovarelli, M. et al. H19 long noncoding RNA controls the mRNA decay promoting function of KSRP. Proc. Natl Acad. Sci. USA 111, E5023–E5028 (2014) .
Kallen, A. N. et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol. Cell 52, 101–112 (2013) .
Yan, L. et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene 34, 3076–3084 (2014) .
Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1393–1406 (2012) .
Nagy, E. & Rigby, W. F. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold). J. Biol. Chem. 270, 2755–2763 (1995) .
Pioli, P. A., Hamilton, B. J., Connolly, J. E., Brewer, G. & Rigby, W. F. Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1. J. Biol. Chem. 277, 35738–35745 (2002) .
Kaffer, C. R., Grinberg, A. & Pfeifer, K. Regulatory mechanisms at the mouse Igf2/H19 locus. Mol. Cell Biol. 21, 8189–8196 (2001) .
Eun, B. et al. The Igf2/H19 muscle enhancer is an active transcriptional complex. Nucleic Acids Res. 41, 8126–8134 (2013) .
Eun, B., Sampley, M. L., Good, A. L., Gebert, C. M. & Pfeifer, K. Promoter cross-talk via a shared enhancer explains paternally biased expression of Nctc1 at the Igf2/H19/Nctc1 imprinted locus. Nucleic Acids Res. 41, 817–826 (2013) .
Fernandez-Sanchez, M. E., Gonatopoulos-Pournatzis, T., Preston, G., Lawlor, M. A. & Cowling, V. H. S-adenosyl homocysteine hydrolase is required for Myc-induced mRNA cap methylation, protein synthesis, and cell proliferation. Mol. Cell Biol. 29, 6182–6191 (2009) .
Barres, R. et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 10, 189–198 (2009) .
Yang, X. et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26, 577–590 (2014) .
Maunakea, A. K. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253–257 (2010) .
Huang, Y. et al. Inhibition of S-adenosylhomocysteine hydrolase by acyclic sugar adenosine analogue D-eritadenine. Crystal structure of S-adenosylhomocysteine hydrolase complexed with D-eritadenine. J. Biol. Chem. 277, 7477–7482 (2002) .
Ctrnacta, V. et al. Efficacy of S-adenosylhomocysteine hydrolase inhibitors, D-eritadenine and (S)-DHPA, against the growth of Cryptosporidium parvum in vitro. Exp. Parasitol. 126, 113–116 (2010) .
Whittle, A. J. et al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149, 871–885 (2012) .
Shalini, S., Dorstyn, L., Dawar, S. & Kumar, S. Old, new and emerging functions of caspases. Cell Death Differ. 22, 526–539 (2014) .
Klingseisen, A. & Jackson, A. P. Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev. 25, 2011–2024 (2011) .
Wang, H., Gauthier, B. R., Hagenfeldt-Johansson, K. A., Iezzi, M. & Wollheim, C. B. Foxa2 (HNF3beta) controls multiple genes implicated in metabolism-secretion coupling of glucose-induced insulin release. J. Biol. Chem. 277, 17564–17570 (2002) .
Sun, X. J. et al. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J. Biol. Chem. 280, 35261–35271 (2005) .
Faber, P. W. et al. Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7, 1463–1474 (1998) .
Kinde, B., Gabel, H. W., Gilbert, C. S., Griffith, E. C. & Greenberg, M. E. Reading the unique DNA methylation landscape of the brain: non-CpG methylation, hydroxymethylation, and MeCP2. Proc. Natl Acad. Sci. USA 112, 6800–6806 (2015) .
Santiago, M., Antunes, C., Guedes, M., Sousa, N. & Marques, C. J. TET enzymes and DNA hydroxymethylation in neural development and function—how critical are they? Genomics 104, 334–340 (2014) .
Wen, L. & Tang, F. Genomic distribution and possible functions of DNA hydroxymethylation in the brain. Genomics 104, 341–346 (2014) .
This work was supported by grant 1-15-BS-084 from the American Diabetes Association to Y.H. and grant R01 HD072418 from the NIGMS to G.G.C.
The authors declare no competing financial interests.
Supplementary Figures 1-7 and Supplementary Tables 1-4 (PDF 659 kb)
Supplementary Data 1
Top 2000 genes strongly hyper- or hypo-methylated in the siH19 relative to siCon control cells. Strongly hypermethylated: 33100% more methylated in siH19 than siCon (pvalue < 0.05); Strongly hypomethylated: 33100% less methylated in siH19 than siCon (pvalue < 0.05). siH19 meth_ratio/siCon meth_ratio: these ratios compare the number of methylated C's to the total number of reads containing that specific CpG. Meth diff: the difference was calculated by subtracting the siCon sample from the siH19 sample. (XLS 729 kb)
Supplementary Data 2
Genes at least 1.5-fold differentially expressed in siH19 over siCon cells. With 1.5-fold change cut-off, 1131 genes or transcripts were found significantly upregulated in siH19 relative to siCon cells, meanwhile 508 genes or transcripts were significantly downregulated. Significant value “TRUE” means that the p value calculated from either siCon or siH19 triplicate samples is < 0.05. (XLS 398 kb)
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Zhou, J., Yang, L., Zhong, T. et al. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. Nat Commun 6, 10221 (2015). https://doi.org/10.1038/ncomms10221
This article is cited by
LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond
Journal of Experimental & Clinical Cancer Research (2022)
Effects of H19/SAHH/DNMT1 on the oxidative DNA damage related to benzo[a]pyrene exposure
Environmental Science and Pollution Research (2022)
Role of long non-coding RNA H19 in the development of osteoporosis
Molecular Medicine (2021)
Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer
Journal of Experimental & Clinical Cancer Research (2021)
Roles of noncoding RNAs in preeclampsia
Reproductive Biology and Endocrinology (2021)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.